profile-img
NEJM

@NEJM

The New England Journal of Medicine is the world’s leading medical journal and website.

calendar_today23-03-2009 04:10:07

31,0K Tweets

941,8K Followers

431 Following

NEJM(@NEJM) 's Twitter Profile Photo
NEJM
@NEJM

1 year ago

A regimen substituting brentuximab vedotin for bleomycin improved 3-year event-free survival among children and adolescents with Hodgkin’s lymphoma by nearly 10 percentage points without a major increase in toxic effects. nej.md/3WkBHOI

A regimen substituting brentuximab vedotin for bleomycin improved 3-year event-free survival among children and adolescents with Hodgkin’s lymphoma by nearly 10 percentage points without a major increase in toxic effects. nej.md/3WkBHOI
account_circle